Company news
Denali Therapeutics Inc. news in 2025
Denali Therapeutics Inc.'s news releases, calls and decks from 2025, newest first.
The New England Journal of Medicine Publishes Phase 1/2 Study of Denali Therapeutics’ Tividenofusp Alfa (DNL310) for Hunter Syndrome (MPS II)
December 29, 2025
PLX: Secarna’s Antisense Oligonucleotide Discovery Collaboration
December 22, 2025
Denali Therapeutics Announces Pricing of Public Offering of Common Stock and Pre-Funded Warrants
December 9, 2025
Denali Therapeutics Announces Proposed Offering of Common Stock and Pre-Funded Warrants
December 8, 2025
Royalty Pharma and Denali Therapeutics Announce $275 Million Royalty Funding Agreement
December 3, 2025
Denali Therapeutics and Royalty Pharma Announce $275 Million Royalty Funding Agreement
December 3, 2025
Denali Therapeutics Reports Third Quarter 2025 Financial Results and Business Highlights
November 5, 2025
Denali Therapeutics Announces Board and Executive Leadership Updates
November 5, 2025
Denali Therapeutics Announces FDA Review Extension of BLA for Tividenofusp Alfa for the Treatment of MPS II (Hunter Syndrome)
October 12, 2025
Denali Therapeutics Reports Second Quarter 2025 Financial Results and Business Highlights
August 10, 2025
Denali Therapeutics Announces FDA Acceptance and Priority Review of Biologics License Application (BLA) for Tividenofusp Alfa for Hunter Syndrome (MPS II)
July 6, 2025
Denali Therapeutics Reports First Quarter 2025 Financial Results and Business Highlights Including Completion of BLA Rolling Submission for Tividenofusp Alfa for Hunter Syndrome
May 5, 2025
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome and Positive Ongoing Interactions with FDA on DNL126 through START Program
April 3, 2025
Denali Therapeutics Announces Initiation of BLA Filing for Accelerated Approval of Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II) and Positive Ongoing Interactions with FDA on DNL126 Through START Program
April 1, 2025
Denali Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results and Business Highlights
February 26, 2025
Denali Therapeutics Announces Primary Analysis and Long-Term Follow-Up of Phase 1/2 Study in Hunter Syndrome (MPS II) with Tividenofusp Alfa
February 5, 2025
Denali Therapeutics Announces Upcoming Presentations on Hunter Syndrome (MPS II) and TransportVehicle™ Enabled Investigational Therapeutic Tividenofusp Alfa at the 2025 WORLDSymposium™
January 29, 2025
Denali Therapeutics Announces Key Anticipated 2025 Milestones and Priorities to Further Advance Its Therapeutics Portfolio for Neurodegeneration and Lysosomal Storage Diseases
January 12, 2025
Denali Therapeutics Announces U.S. FDA Breakthrough Therapy Designation Granted to Tividenofusp Alfa for the Treatment of Hunter Syndrome (MPS II)
January 7, 2025
Denali Therapeutics Announces Topline Results for Regimen G Evaluating eIF2B Agonist DNL343 in the Phase 2/3 HEALEY ALS Platform Trial
January 5, 2025
Decks in 2025
- Investor Day (December 2025)
Investor day · 136 slides · Dec 4, 2025